FABINO ENTERPRISES LIMITED is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 21 | 18 | 21 |
| EBITDA (ex other income) | — | — | — |
| margin % | — | — | — |
| Owners' profit | — | — | — |
| EPS, as reported (₹) | 0.17 | 0.29 | 2.66 |
| ROE % · ROCE % | — · 1.6 | — · 5.3 | — · (11.5) |
| Debt / equity (x) | — | — | — |
| Cash from operations | (1) | 0 | 0 |
| Capex | — | (0) | (0) |
| ₹ crore | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 13 | 8 | 4 | 14 | 7 | 14 |
| Profit before tax | 0 | (0) | 0 | 0 | (0) | (1) |
| Net profit | — | — | — | — | — | — |
| EPS (₹) | 0.42 | (0.25) | 0.13 | 0.16 | 0.89 | 1.78 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 6 Sept 2026 · Newspaper publication of 15th AGM notice by Fabino Enterprises | compliance | minimal | — | — |
| 4 Sept 2026 · Fabino Enterprises files FY26 Annual Report and 15th AGM Notice | board shareholder meetings | medium | — | — |
| 4 Sept 2026 · Fabino Enterprises 15th AGM on Sept 29, 2026; subsidiary sale proposed | board shareholder meetings | low | — | — |
| 4 Sept 2026 · Board approves subsidiary sale, re-appoints director and auditor | management changes | medium | — | — |
| 4 Sept 2026 · Fabino board approves subsidiary sale, re-appoints director and auditor | management changes | medium | — | — |
| 22 Jul 2026 · Open offer poorly subscribed; acquirers take over Fabino at 56.96% | compliance | minimal | — | — |
| 16 Jul 2026 · Quarterly RTA Certificate Under SEBI Regulation 74(5) for Period Ended June 2026 | compliance | minimal | — | — |
| 16 Jul 2026 · Mrs. Shipra Rathi appointed as Company Secretary of Fabino Enterprises | management changes | medium | — | — |
| 16 Jul 2026 · Mrs. Shipra Rathi appointed as Company Secretary and KMP | management changes | medium | — | — |
| 7 Jul 2026 · Company Secretary and Compliance Officer resigns | management changes | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| LAURUS LABS LIMITED |
| 1,06,375 |
| 97.2 |
| 19.59 |
| 59.3 |
| 16.4 |
| 17.2 |
| 7.2 |
| 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 6.9 | 28.9 | 15 of 169 | 92% |
| ROCE | (14.0) | 10.8 | 170 of 183 | 7% |
| Revenue growth | 72.8 | 16.3 | 14 of 161 | 92% |
| Market cap | 4 | 839 | 181 of 182 | 1% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
